ArticleHead & neck2025
Efficacy of Eribulin Monotherapy in Patients With Unresectable and/or Metastatic Adenoid Cystic Carcinoma Receiving Platinum-Based Therapy.
Article in Head & neck, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdenoid cystic carcinoma (ACC) is the second most common and treatment-resistant salivary gland carcinoma (SGC). Although platinum-based therapies are effective, the efficacy of eribulin, a microtubule inhibitor with an 18% response rate in a Phase II trial involving recurrent/metastatic SGC, in patients with advanced ACC after platinum therapy remains unclear.
methodsWe retrospectively analyzed 19 patients with unresectable/metastatic ACC treated with platinum-based therapy between December 2015 and January 2023 at the National Cancer Center Hospital, Japan. Ten patients received eribulin.
resultsThe median age was 61 years. 84% achieved disease control with the first-line or later platinum-based therapy (median progression-free survival [mPFS]: 7.6 months). Second-line or later eribulin monotherapy yielded a 50% disease control rate, with mPFS of 3.7 months and median overall survival of 41.7 months. The adverse events, predominantly neutropenia, were manageable.
conclusionEribulin shows promising effects of unresectable/metastatic ACC, offering tolerable adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.